Global Gastroparesis Drugs Market 2017-2021
About Gastroparesis Drugs
Gastroparesis also known as delayed gastric emptying, is a disorder that stops or slows the movement of food through the digestive tract. Normally, the vagus nerve controls the stomach muscles, which are responsible for the movement of food in the stomach. These muscles contract to break up the food and lead to its movement through the gastrointestinal tract. Gastroparesis can be caused due to the damage of vagus nerve by illness or injury. The disease does not have complete remission; however, proper medications along with the changes in diet can provide relief.
Technavio’s analysts forecast the global gastroparesis drugs market to grow at a CAGR of 3.54% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global gastroparesis drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Gastroparesis Drugs Market 2017-2021
Technavio recognizes the following companies as the key players in the global gastroparesis drugs market: Cadila Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson, and Valeant.
Other Prominent Vendors in the market are: Evoke Pharma, Teva Pharmaceutical Industries, and Theravance Biopharma.
Commenting on the report, an analyst from Technavio’s team said: “One trend in market is fast track approvals and acquisitions to change the phase of the market. High unmet needs in the treatment of gastroparesis have led the fast track approvals of certain drugs. For example, in 2016, Theravance Biopharma received the US FDA fast track designation for velusetrag for idiopathic and diabetic gastroparesis. At present, the drug is in Phase II clinical stage. The fast track approval by the US FDA is done to facilitate the need to treat serious conditions associated with gastroparesis.”
According to the report, one driver in market is rising gastric surgeries fueling the prevalence rate of post-surgical gastroparesis. Post-surgical gastroparesis is the third most common type of the gastroparesis after idiopathic and diabetic gastroparesis. Gastric surgeries include surgeries that are done to digestive parts of the bodies such as the esophagus, duodenum, and stomach. During the gastric surgery, there is a high chance that the vagus nerves get injured. Injury to these nerves is the major cause of gastroparesis. Some of the common types of gastric surgeries are gastric bypass surgeries and bariatric surgeries. Rising obesity is a major reason for these surgeries. As one of the major aims of these surgeries is weight loss. Vagus nerve damage is one of the major complications associated with gastric bypass. Sleeve gastrectomy has also seen to alter the gut-brain communication.
Further, the report states that one challenges in market is weak pipeline for gastroparesis. The weak pipeline of gastroparesis is a huge challenge for the gastroparesis drugs market. At present Metozolv ODT (metoclopramide hydrochloride) is the only US FDA-approved drug used for the treatment of diabetic gastroparesis. The situation is even worse for idiopathic gastroparesis, which does not have any US FDA-approved drug for its treatment. Even though there are very limited options available for the treatment of gastroparesis, the pipeline is quite thin. Most of the drugs currently in the pipeline focus on diabetic gastroparesis, which suggests that idiopathic gastroparesis is still an un-addressed segment of the market. The R&D process for idiopathic gastroparesis becomes even more difficult because of lack of knowledge regarding the actual cause of the disease. Current drug development for gastroparesis lags behind many other pharmaceutical developments. This restricts the growth of gastroparesis market. Also, termination of clinical trials is expected to hamper the market growth. For instance, GlaxoSmithKline and Adolor received a letter of approval for a New Drug Application (NDA) for alvimopan, a new drug for the treatment of IBS, slow transit constipation, and gastroparesis. However, it was later suspended due to long-term safety concerns.
Cadila Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson, Valeant, Evoke Pharma, Teva Pharmaceutical Industries, and Theravance Biopharma.